Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy

Nature Reviews Cancer

Volumn 14, Issue 2, 2014, Pages 135-146

  Coulie, Pierre G ^a,c   Van Den Eynde, Benoît J ^a,b,c   Van Der Bruggen, Pierre ^a,b,c   Boon, Thierry ^a,b  

^a DE DUVE INSTITUTE   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c Welbio (Walloon Excellence in Lifesciences and Biotechnology)   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84894559188     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3670     Document Type: Review

References (195)

1. Klein, G. & Klein, E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc. Natl Acad. Sci. USA 74, 2121-2125 (1977).
2. Gross, L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 326-333 (1943).
3. Prehn, R. T. & Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957).
4. Hewitt, H. B., Blake, E. R. & Walder, A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33, 241-259 (1976).
5. Boon, T. & Kellermann, O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl Acad. Sci. USA 74, 272-275 (1977).
6. Boon, T., Kellermann, O., Mathy, E. & Gaillard, J. A. in Teratomas and Differentiation (eds Sherman, M. & Solter, D.) 161-166 (Academic Press, 1975).
7. Boon, T. & Van Pel, A. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl Acad. Sci. USA 75, 1519-1523 (1978).
8. Van Pel, A. & Boon, T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl Acad. Sci. USA 79, 4718-4722 (1982).
9. Claman, H. N., Chaperon, E. A. & Triplett, R. F. Thymus-marrow cell combinations. synergism in antibody production. Proc. Soc. Exp. Biol. Med. 122, 1167-1171 (1966).
10. Miller, J. F. A. P. & Mitchell, G. F. The thymus and the precursors of antigen reactive cells. Nature 216, 659-663 (1967).
11. Cerottini, J. C. & Brunner, K. T. Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv. Immunol. 18, 67-132 (1974).
12. Rouse, B. T., Rollinghoff, M. & Warner, N. L. Anti-theta serum-induced supression of the cellular transfer of tumour-specific immunity to a syngeneic plasma cell tumour. Nature New Biol. 238, 116-117 (1972).
13. Uyttenhove, C., Van Snick, J. & Boon, T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J. Exp. Med. 152, 1175-1183 (1980).
14. Boon, T., Van Snick, J., Van Pel, A., Uyttenhove, C. & Marchand, M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J. Exp. Med. 152, 1184-1193 (1980).
15. Gillis, S. & Smith, K. A. Long term culture of tumour-specific cytotoxic T cells. Nature 268, 154-156 (1977).
16. Maryanski, J. L., Van Snick, J., Cerottini, J. C. & Boon, T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur. J. Immunol. 12, 401-406 (1982).
17. Maryanski, J. L., Marchand, M., Uyttenhove, C. & Boon, T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Int. J. Cancer 31, 119-123 (1983).
18. Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040-1052 (1983).
19. Wheelock, E. F., Weinhold, K. J. & Levich, J. The tumor dormant state. Adv. Cancer Res. 34, 107-140 (1981).
20. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
21. Zinkernagel, R. M. & Doherty, P. C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701-702 (1974).
22. Townsend, A. R. M. et al. The epitopes of Influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959-968 (1986).
23. Bjorkman, P. et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506 (1987).
24. Van Pel, A., De Plaen, E. & Boon, T. Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell. Mol. Genet. 11, 467-475 (1985).
25. De Plaen, E. et al. Immunogenic (tum?) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc. Natl Acad. Sci. USA 85, 2274-2278 (1988).
26. Lurquin, C. et al. Structure of the gene of tum? transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58, 293-303 (1989).
27. Szikora, J. P. et al. Structure of the gene of tum? transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J. 9, 1041-1050 (1990).
28. Sibille, C. et al. Structure of the gene of tum? transplantation antigen P198: a point mutation generates a new antigenic peptide. J. Exp. Med. 172, 35-45 (1990).
29. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E. & Boon, T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373-1384 (1991).
30. Ramarathinam, L. et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 155, 5323-5329 (1995).
31. Boon, T. et al. Genes coding for tumor-specific rejection antigens. Cold Spring Harb. Symp. Quant. Biol. 59, 617-622 (1994).
32. Brandle, D. et al. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28, 4010-4019 (1998).
33. Livingston, P. O. et al. Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int. J. Cancer 24, 34-44 (1979).
34. Vanky, F. & Klein, E. Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int. J. Cancer 29, 547-553 (1982).
35. Vose, B. M. & Bonnard, G. D. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2. Int. J. Cancer 29, 33-39 (1982).
36. Knuth, A., Danowski, B., Oettgen, H. F. & Old, L. J. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl Acad. Sci. USA 81, 3511-3515 (1984).
37. Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676-1680 (1988).
38. H?in, M. et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer 39, 390-396 (1987).
39. Van den Eynde, B. et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer 44, 634-640 (1989).
40. van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991).
41. Fiszer, D. & Kurpisz, M. Major histocompatibility complex expression on human, male germ cells: a review. Am. J. Reprod. Immunol. 40, 172-176 (1998).
42. Traversari, C. et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176, 1453-1457 (1992).
43. De Plaen, E. et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40, 360-369 (1994).
44. Lurquin, C. et al. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics 46, 397-408 (1997).
45. Muscatelli, F., Walker, A. P., De Plaen, E., Stafford, A. N. & Monaco, A. P. Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc. Natl Acad. Sci. USA 92, 4987-4991 (1995).
46. Lucas, S., De Plaen, E. & Boon, T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 87, 55-60 (2000).
47. Lucas, S. et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. 58, 743-752 (1998).
48. Boël, P. et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2, 167-175 (1995).
49. Van den Eynde, B. et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182, 689-698 (1995).
50. Coulie, P. G. et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92, 7976-7980 (1995).
51. Wölfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
52. Brandle, D., Brasseur, F., Weynants, P., Boon, T. & Van den Eynde, B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183, 2501-2508 (1996).
53. Robbins, P. F. et al. A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185-1192 (1996).
54. Brichard, V. et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489-495 (1993).
55. Topalian, S. L. et al. Melanoma-specific CD4+T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183, 1965-1971 (1996).
56. Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92, 11810-11813 (1995).
57. Smith, H. A. & McNeel, D. G. The SSX family of cancertestis antigens as target proteins for tumor therapy. Clin. Dev. Immunol. 2010, 150591 (2010).
58. Chen, Y. T. et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94, 1914-1918 (1997).
59. Chen, Y.-T. Identification of human tumor antigens by serological expression cloning: an online review on SEREX. Cancer Immun. [online], http://www. cancerimmunity.org/serex (2004).
60. Rotzschke, O. et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348, 252-254 (1990).
61. Cox, A. L. et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719 (1994).
62. Skipper, J. C. et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183, 527-534 (1996).
63. Dalet, A. et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl Acad. Sci. USA 108, E323-E331 (2011).
64. Parker, K. C., Bednarek, M. A. & Coligan, J. E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains. J. Immunol. 152, 163-175 (1994).
65. Rammensee, H.-G., Bachmann, J. & Stevanovic, S. MHC Ligands and Peptide Motifs (Springer, 1997).
66. van der Bruggen, P. et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24, 3038-3043 (1994).
67. Chaux, P. et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163, 2928-2936 (1999).
68. Chaux, P. et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J. Exp. Med. 189, 767-778 (1999).
69. van der Bruggen, P. et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188, 51-64 (2002).
70. Gambacorti-Passerini, C. et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR a present in acute promyelocytic leukemia cells. Blood 81, 1369-1375 (1993).
71. ten Bosch, G. J., Joosten, A. M., Kessler, J. H., Melief, C. J. & Leeksma, O. C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88, 3522-3527 (1996).
72. Tsang, K. Y. et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87, 982-990 (1995).
73. van der Bruggen, P., Stroobant, V., Vigneron, N. & Van den Eynde, B. Peptide database: T cell-defined tumor antigens. Cancer Immun. [online], http://www.cancerimmunity.org/peptide/(2013).
74. Long, H. M., Parsonage, G., Fox, C. P. & Lee, S. P. Immunotherapy for Epstein-Barr virus-associated malignancies. Drug News Perspect. 23, 221-228 (2010).
75. van der Burg, S. H. & Melief, C. J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 23, 252-257 (2011).
76. Fujita, Y., Rooney, C. M. & Heslop, H. E. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 41, 193-198 (2008).
77. Ramos, J. C. & Lossos, I. S. Newly emerging therapies targeting viral-related lymphomas. Curr. Oncol. Rep. 13, 416-426 (2011).
78. Lennerz, V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013-16018 (2005).
79. Network, C. G. A. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
80. Mandruzzato, S., Brasseur, F., Andry, G., Boon, T. & van der Bruggen, P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186, 785-793 (1997).
81. Yotnda, P. et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101, 2290-2296 (1998).
82. Yotnda, P. et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102, 455-462 (1998).
83. Makita, M. et al. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia 16, 2400-2407 (2002).
84. Yun, C. et al. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 54, 153-161 (1999).
85. Boczkowski, D., Nair, S. K., Nam, J. H., Lyerly, H. K. & Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028-1034 (2000).
86. Van Tendeloo, V. F. et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98, 49-56 (2001).
87. Weber, J. et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2.-deoxycytidine. Cancer Res. 54, 1766-1771 (1994).
88. De Smet, C. et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93, 7149-7153 (1996).
89. Grunau, C. et al. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 43, 11-24 (2005).
90. Gjerstorff, M. F., Kock, K., Nielsen, O. & Ditzel, H. J. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Hum. Reprod. 22, 953-960 (2007).
91. Wölfel, T. et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24, 759-764 (1994).
92. Coulie, P. G. et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42 (1994).
93. Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347-352 (1994).
94. Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91, 3515-3519 (1994).
95. Bakker, A. B. et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62, 97-102 (1995).
96. Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91, 6458-6462 (1994).
97. Pittet, M. J. et al. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190, 705-715 (1999).
98. Lonchay, C. et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14631-14638 (2004).
99. Chaux, P., Vantomme, V., Coulie, P., Boon, T. & van der Bruggen, P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer 77, 538-542 (1998).
100. Alanio, C., Lemaitre, F., Law, H. K., Hasan, M. & Albert, M. L. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 115, 3718-3725 (2010).
101. Zippelius, A. et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195, 485-494 (2002).
102. Romero, P. et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigenexperienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188, 1641-1650 (1998).
103. Correale, P. et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl Cancer Inst. 89, 293-300 (1997).
104. Olson, B. M. et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol. Immunother. 59, 943-953 (2010).
105. Fisk, B., Blevins, T. L., Wharton, J. T. & Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181, 2109-2117 (1995).
106. Inoue, K. et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405-1412 (1997).
107. Cilloni, D. et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16, 2115-2121 (2002).
108. Chapuis, A. G. et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 5, 174ra27 (2013).
109. Vlad, A. M., Kettel, J. C., Alajez, N. M., Carlos, C. A. & Finn, O. J. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249-293 (2004).
110. Giraud, M. et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 448, 934-937 (2007).
111. Gotter, J., Brors, B., Hergenhahn, M. & Kyewski, B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199, 155-166 (2004).
112. Huijbers, I. J. et al. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. J. Immunol. 188, 111-121 (2012).
113. Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691-2697 (2012).
114. Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151 (2013).
115. Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 122, 863-871 (2013).
116. Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626 (2011).
117. Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22 (2006).
118. Quaglino, P. et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a singleinstitution hospital-based observational cohort study. Ann. Oncol. 21, 409-414 (2010).
119. Khammari, A. et al. Long-term follow-up of patients treated by adoptive transfer of melanoma tumorinfiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol. Immunother. 56, 1853-1860 (2007).
120. Yeh, S. et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116, 981-989 (2009).
121. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
122. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
123. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
124. Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 305, 200-205 (2004).
125. Gattinoni, L., Powell, D. J. Jr, Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nature Rev. Immunol. 6, 383-393 (2006).
126. Germeau, C. et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201, 241-248 (2005).
127. Lurquin, C. et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201, 249-257 (2005).
128. Carrasco, J. et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 180, 3585-3593 (2008).
129. Coulie, P. G. et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50, 289-297 (1992).
130. Boon, T., Coulie, P. G., Van den Eynde, B. J. & van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006).
131. Gajewski, T. F. et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131-145 (2006).
132. Guillaume, B. et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc. Natl Acad. Sci. USA 107, 18599-18604 (2010).
133. Morel, S. et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12, 107-117 (2000).
134. Schultz, E. S. et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 195, 391-399 (2002).
135. Chapiro, J. et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176, 1053-1061 (2006).
136. Guillaume, B. et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J. Immunol. 189, 3538-3547 (2012).
137. Hanada, K., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252-256 (2004).
138. Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587-590 (2004).
139. Parmentier, N. et al. Production of an antigenic peptide by insulin-degrading enzyme. Nature Immunol. 11, 449-454 (2010).
140. Kessler, J. H. et al. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nature Immunol. 12, 45-53 (2011).
141. Rogner, U. C., Wilke, K., Steck, E., Korn, B. & Poustka, A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 29, 725-731 (1995).
142. Doyle, J. M., Gao, J., Wang, J., Yang, M. & Potts, P. R. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 39, 963-974 (2010).
143. Monte, M. et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA 103, 11160-11165 (2006).
144. Yang, B. et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67, 9954-9962 (2007).
145. Bai, S., He, B. & Wilson, E. M. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol. Cell. Biol. 25, 1238-1257 (2005).
146. Wang, J. et al. Induced malignant genome reprogramming in somatic cells by testis-specific factors. Biochim. Biophys. Acta 1809, 221-225 (2011).
147. Laduron, S. et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res. 32, 4340-4350 (2004).
148. Nagao, T. et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J. Biol. Chem. 278, 10668-10774 (2003).
149. Peikert, T., Specks, U., Farver, C., Erzurum, S. C. & Comhair, S. A. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res. 66, 4693-4700 (2006).
150. Gaugler, B. et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921-930 (1994).
151. Duffour, M.-T. et al. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur. J. Immunol. 29, 3329-3337 (1999).
152. Panelli, M. C. et al. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol. 164, 4382-4392 (2000).
153. Ma, W. et al. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int. J. Cancer 109, 698-702 (2004).
154. Ruault, M. et al. New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur. J. Hum. Genet. 10, 833-840 (2002).
155. Ruault, M. et al. BAGE genes generated by juxtacentromeric reshuffling in the Hominidae lineage are under selective pressure. Genomics 81, 391-399 (2003).
156. Gjerstorff, M. F. & Ditzel, H. J. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens 71, 187-192 (2008).
157. Cilensek, Z. M., Yehiely, F., Kular, R. K. & Deiss, L. P. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-., taxol and.-irradiation. Cancer Biol. Ther. 1, 380-387 (2002).
158. Zendman, A. J., Van Kraats, A. A., Weidle, U. H., Ruiter, D. J. & Van Muijen, G. N. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. Int. J. Cancer 99, 361-369 (2002).
159. Shimono, M. et al. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells. Int. J. Oncol. 30, 835-840 (2007).
160. Jager, E. et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-270 (1998).
161. Chen, Y. T. et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl Acad. Sci. USA 95, 6919-6923 (1998).
162. Güre, A. O., Wei, I. J., Old, L. J. & Chen, Y. T. The SSX gene family: characterization of 9 complete genes. Int. J. Cancer 101, 448-453 (2002).
163. Lim, F. L., Soulez, M., Koczan, D., Thiesen, H. J. & Knight, J. C. A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 17, 2013-2018 (1998).
164. Thaete, C. et al. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum. Mol. Genet. 8, 585-591 (1999).
165. Ayyoub, M. et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168, 1717-1722 (2002).
166. Yang, R., Morosetti, R. & Koeffler, H. P. Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res. 57, 913-920 (1997).
167. Wolgemuth, D. J. Function of the A-type cyclins during gametogenesis and early embryogenesis. Results Probl. Cell Differ. 53, 391-413 (2011).
168. Ochsenreither, S. et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 119, 5492-5501 (2012).
169. Fukuyama, T. et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 66, 4922-4928 (2006).
170. Park, H. J. et al. The centrosomal localization of KM-HN-1 (MGC33607) depends on the leucine zipper motif and the C-terminal coiled-coil domain. Exp. Mol. Med. 39, 828-838 (2007).
171. Monji, M. et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin. Cancer Res. 10, 6047-6057 (2004).
172. Martelange, V., De Smet, C., De Plaen, E., Lurquin, C. & Boon, T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res. 60, 3848-3855 (2000).
173. Miyahara, Y. et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin. Cancer Res. 11, 5581-5589 (2005).
174. Lim, S. H., Wang, Z., Chiriva-Internati, M. & Xue, Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 97, 1508-1510 (2001).
175. Frayne, J. & Hall, L. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction 124, 767-774 (2002).
176. Chiriva-Internati, M., Wang, Z., Pochopien, S., Salati, E. & Lim, S. H. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int. J. Cancer 107, 863-865 (2003).
177. Lucas, S., Brasseur, F. & Boon, T. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res. 59, 4100-4103 (1999).
178. Chomez, P. et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61, 5544-5551 (2001).
179. Alpen, B., Gure, A. O., Scanlan, M. J., Old, L. J. & Chen, Y. T. A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. Gene 297, 141-149 (2002).
180. Egland, K. A., Kumar, V., Duray, P. & Pastan, I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol. Cancer Ther. 1, 441-450 (2002).
181. Türeci, Ö. et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56, 4766-4772 (1996).
182. Smith, H. A., Cronk, R. J., Lang, J. M. & McNeel, D. G. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 71, 6785-6795 (2011).
183. Brunner, K. T., Mauel, J., Cerottini, J.-C. & Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14, 181-196 (1968).
184. Holm, G. & Perlmann, P. Quantitative studies on phytohaemagglutinin- induced cytotoxicity by human lymphocytes against homologous cells in tissue culture. Immunology 12, 525-536 (1967).
185. Levy, J. P. & Leclerc, J. C. The murine sarcoma virus-induced tumor:
186. Bjorkman, P. J. et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329, 512-518 (1987).
187. Topalian, S. L. et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl Acad. Sci. USA 91, 9461-9465 (1994).
188. Leth-, B. et al. LAGE-1, a new gene with tumor specificity. Int. J. Cancer 76, 903-908 (1998).
189. Guilloux, Y. et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183, 1173-1183 (1996).
190. Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F. & Rosenberg, S. A. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183, 1131-1140 (1996).
191. Lupetti, R. et al. Translation of a retained intron in tyrosinase-related protein (TRP)-2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J. Exp. Med. 188, 1005-1016 (1998).
192. Van den Eynde, B. J. et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J. Exp. Med. 190, 1793-1800 (1999).
193. Aarnoudse, C. A., van den Doel, P. B., Heemskerk, B. & Schrier, P. I. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 82, 442-448 (1999).
194. Probst-Kepper, M. et al. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J. Exp. Med. 193, 1189-1198 (2001).
195. Ohminami, H., Yasukawa, M. & Fujita, S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95, 286-293 (2000).